WuXi AppTec

WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. 

The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. 

The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.

WuXi's founder is Dr Ge Li, an organic chemist, who founded WuXi PharmaTech in Shanghai in December 2000. WuXi established services in synthetic chemistry in 2001, manufacturing process development in 2003, research manufacturing in 2004, bioanalytical services in 2005, service biology in 2006, and toxicology and formulation in 2007. 

On December 14, 2006, WuXi PharmaTech announced that it was ranked 173rd on the Deloitte Technology Fast 500 Asia Pacific. The company opened chemistry facilities in Tianjin the next year. In 2008, WuXi PharmaTech acquired AppTec Laboratory Services Inc., a US-based company founded in 2001 with expertise in medical-device and biologics testing and with facilities in St. Paul, MN; Philadelphia, PA; and Atlanta, GA. WuXi opened a toxicology facility in Suzhou in 2009. 

WuXi opened a large-scale manufacturing facility in Jinshan in 2010. The company began a biologics discovery, development, and manufacturing operation in Shanghai and Wuxi City in 2011. In the same year, WuXi acquired MedKey, a China-based clinical research company, and Abgent, a San Diego company and one of the world's largest manufacturers of antibodies for biological research and drug discovery. In 2012, WuXi opened a chemistry facility in Wuhan and a GMP biologics drug-substance facility in Wuxi City. That year WuXi also entered into a joint venture with MedImmune, the biologics arm of AstraZeneca, to co-develop MEDI5117, an anti-IL6 antibody for rheumatoid arthritis for the Chinese market. 

In 2013, WuXi formed a joint venture with the global clinical contract research organization PRA International to build a clinical research business in China. In 2014, WuXi opened a new biologics biosafety testing facility in Suzhou. In the same year, WuXi acquired XenoBiotic Laboratories, Inc., a contract research organization with 27 years of operation that provides bioanalytical, drug metabolism, and pharmacokinetic services to the pharmaceutical, animal health, and agrochemical industries. 

In 2015, WuXi completed its merger with WuXi Merger Limited, a wholly-owned subsidiary of New WuXi Life Science Limited. As a result of the merger, New WuXi Life Science Limited acquired the company in a cash transaction valued at approximately US$3.3 billion. In 2016, WuXi's STA subsidiary opened a new campus in Changzhou and operations in San Diego. In the same year, WuXi acquired Crelux GmbH, a structure-based drug discovery provider based in Munich, Germany. In 2017, WuXi acquired HD Biosciences, a biology-focused preclinical drug discovery contract research organization.

WuXi AppTec's mission is to "advance and improve the quality of life for people around the world." 

WuXi AppTec aims to achieve this mission by providing comprehensive and integrated drug discovery, development, and manufacturing services to its clients in the pharmaceutical, biotechnology, and medical device industries.

WuXi AppTec's vision is to be "the most trusted and valued global partner for enabling life-changing therapies." 

The company is committed to achieving this vision by providing high-quality, innovative, and cost-effective services that help its clients bring new medicines and medical devices to market. WuXi AppTec also strives to be a responsible corporate citizen, promoting sustainability, diversity, and ethical business practices in all aspects of its operations.

• Drug discovery services: WuXi AppTec offers a comprehensive suite of services to support drug discovery, including target identification and validation, hit identification and optimization, and preclinical development.
• Development and manufacturing services: The company offers a range of services to support drug development and manufacturing, including process research and development, analytical and formulation development, and manufacturing of clinical trial materials and commercial products.
• Testing and analysis services: WuXi AppTec provides a broad range of testing and analysis services to support drug development and regulatory submissions, including safety assessment, bioanalytical services, and quality control testing.
• Medical device services: The company offers a range of services to support the development and manufacturing of medical devices, including product design and development, prototyping, and testing and validation.
• Laboratory and research services: WuXi AppTec operates a network of laboratory facilities that provide a broad range of research services, including genomics and proteomics, biomarker discovery, and toxicology testing.
• Clinical research services: The company offers a range of clinical research services, including clinical trial management, monitoring, and data management.